These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 20852269)

  • 21. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities.
    Gerondelis P; Archer RH; Palaniappan C; Reichman RC; Fay PJ; Bambara RA; Demeter LM
    J Virol; 1999 Jul; 73(7):5803-13. PubMed ID: 10364332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
    Melikian GL; Rhee SY; Varghese V; Porter D; White K; Taylor J; Towner W; Troia P; Burack J; Dejesus E; Robbins GK; Razzeca K; Kagan R; Liu TF; Fessel WJ; Israelski D; Shafer RW
    J Antimicrob Chemother; 2014 Jan; 69(1):12-20. PubMed ID: 23934770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
    Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
    J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
    Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
    J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients.
    Gianotti N; Galli L; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Lazzarin A; Clementi M; Castagna A
    New Microbiol; 2005 Oct; 28(4):319-26. PubMed ID: 16386016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
    Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
    Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
    J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
    Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
    J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
    Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
    J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
    J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency.
    Wang J; Dykes C; Domaoal RA; Koval CE; Bambara RA; Demeter LM
    Virology; 2006 May; 348(2):462-74. PubMed ID: 16504235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.